ANX1502 — Initial data
Fall 2026
Next Milestone: Update on POC trial in CAD anticipated in the Fall of 2026.Source filing
ANNX biotech catalysts & pipeline
ANNEXON INC · Data as of 2026-09-08
Upcoming catalysts
tanruprubart (formerly ANX005) — NDA/BLA submission
Q4 2026
Next Milestone: Biologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.Source filing
Vonaprument (formerly ANX007) — Topline data
Q4 2026
Next Milestones: Month 15 primary endpoint on track for the fourth quarter of 2026, with final trial completion, including the Month 24 primary endpoint expected in the third quarter of 2027.Source filing
Vonaprument (formerly ANX007) — Full data
Q3 2027
Next Milestones: Month 15 primary endpoint on track for the fourth quarter of 2026, with final trial completion, including the Month 24 primary endpoint expected in the third quarter of 2027.Source filing